COMMUNIQUÉS West-GlobeNewswire

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
26/06/2025
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of [...]
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
26/06/2025
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well [...]
XORTX Announces USD $925,000 Private Placement
26/06/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX [...]
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
26/06/2025
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA ® at medical [...]
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
26/06/2025
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
26/06/2025
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse [...]
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
26/06/2025
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to [...]
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
26/06/2025
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 [...]
World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
26/06/2025
Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE) In just six months, IM8 is one of the fastest growing supplement brands in the world, generating an extraordinary [...]
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
26/06/2025
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
26/06/2025
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
26/06/2025
ALK ( ALKB:DC / OMX: ALK B ) today announced the first market launch of EURneffy ® 2 mg (the trade name for neffy ® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency [...]
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
26/06/2025
First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women. The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable populations. [...]
26 ZAZA THCA Flower Strains Unleashed: The Hemp Doctor’s Largest Drop Yet
26/06/2025
MOORESVILLE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, America’s premier hemp and cannabinoid brand, introduces its largest THCA flower collection release with 26 indoor-grown unique strains handpicked [...]
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
26/06/2025
Saint-Herblain, France, June 26, 2025 – Valneva SE , (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza [...]
Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne
26/06/2025
Saint-Herblain, France, le 26 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui un accord exclusif avec CSL Seqirus, l'une des plus grandes [...]
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
26/06/2025
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and [...]
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
26/06/2025
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing [...]
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
25/06/2025
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for [...]

Pages